Literature DB >> 15027503

A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer.

Bernard F Cole1, Richard D Gelber, Shari Gelber, Pabak Mukhopadhyay.   

Abstract

Quality of life is an important component in the evaluation of therapies, especially in advanced cancer. Methods available for the analysis of longitudinal quality-of-life data include linear mixed models (including growth curve models), generalized linear models, generalized estimating equations, and joint modeling of quality of life and the missingness process. Quality-adjusted survival (Q-TWiST) has also been useful to compare treatments. By weighting the durations of health states according to their quality of life, one arrives at a single end point reflecting the duration of survival and the quality of life. We propose methods for incorporating longitudinal quality-of-life data into quality-adjusted survival. We divide follow-up time into two states, "poor" and "good," based on a cut-off applied to observed quality-of-life scores. Disease progression is handled as a separate state. We then use survival analysis methods to estimate the mean duration of each state as well as mean quality-adjusted time. The analysis is repeated by varying the cut-off to illustrate the range of possible results. Finally a single summary analysis is achieved by averaging (possibly with weights) across the cut-offs used. We illustrate the methodology using data from a cancer clincial trial.

Entities:  

Mesh:

Year:  2004        PMID: 15027503     DOI: 10.1081/BIP-120028509

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  10 in total

1.  Evaluation of benefit-risk.

Authors:  Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Analysis of longitudinal health-related quality of life data with terminal events.

Authors:  Zhezhen Jin; Mengling Liu; Steven Albert; Zhiliang Ying
Journal:  Lifetime Data Anal       Date:  2006-07-01       Impact factor: 1.588

3.  Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.

Authors:  Arthur S Zbrozek; Gary Hudes; Donna Levy; Andrew Strahs; Anna Berkenblit; Robert DeMarinis; Shreekant Parasuraman
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Patient preferences in advanced or recurrent ovarian cancer.

Authors:  Laura J Havrilesky; Angeles Alvarez Secord; Jessie A Ehrisman; Andrew Berchuck; Fidel A Valea; Paula S Lee; Stephanie L Gaillard; Greg P Samsa; David Cella; Kevin P Weinfurt; Amy P Abernethy; Shelby D Reed
Journal:  Cancer       Date:  2014-08-04       Impact factor: 6.860

5.  Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.

Authors:  Jennifer L Beaumont; John M Salsman; Jose Diaz; Keith C Deen; Lauren McCann; Thomas Powles; Michelle D Hackshaw; Robert J Motzer; David Cella
Journal:  Cancer       Date:  2016-01-27       Impact factor: 6.860

6.  Calibration of quality-adjusted life years for oncology clinical trials.

Authors:  Jeff A Sloan; Daniel J Sargent; Paul J Novotny; Paul A Decker; Randolph S Marks; Heidi Nelson
Journal:  J Pain Symptom Manage       Date:  2013-11-15       Impact factor: 3.612

7.  A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.

Authors:  J Wang; Z Zhao; B Barber; B Sherrill; M Peeters; J Wiezorek
Journal:  Br J Cancer       Date:  2011-05-24       Impact factor: 7.640

8.  Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance).

Authors:  Brittny T Major-Elechi; Paul J Novotny; Jasvinder A Singh; James A Bonner; Amylou C Dueck; Daniel J Sargent; Axel Grothey; Jeff A Sloan
Journal:  Int J Stat Med Res       Date:  2018-11-16

9.  Observation as a treatment strategy for advanced renal cell carcinoma-a call for prospective validation.

Authors:  Rosalie Fisher; Alexandra Pender; Kiruthikah Thillai; Simon Chowdhury; Lisa Pickering; Komel Khabra; Martin Gore; James Larkin
Journal:  Front Oncol       Date:  2012-10-31       Impact factor: 6.244

10.  Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer.

Authors:  J Bernhard; D Zahrieh; A S Coates; R D Gelber; M Castiglione-Gertsch; E Murray; J F Forbes; L Perey; J Collins; R Snyder; C-M Rudenstam; D Crivellari; A Veronesi; B Thürlimann; M F Fey; K N Price; A Goldhirsch; C Hürny
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.